Protalix’s (NYSE:PLX) long-suffering bulls finally have reason to celebrate: The Israeli biotech firm announced this morning the expansion of its partnership with Chiesi. Protalix and …
Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from …
Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race …
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its financial results for the nine months ended September 30, 2017 and provided a corporate update. “I am excited …
It’s a very rewarding trading day for investors in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) with shares up over 35%, making the stock Wall Street’s …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% whirl down despite the biotech firm posting a …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its financial results for the six months ended June 30, 2017 and provided a corporate update. “Substantial progress was …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced today that phase II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that a Supplemental New Drug Application (sNDA) submitted to the U.S.
In a research report released Monday, Rodman & Renshaw analyst Ram Selvaraju reiterated a Buy rating on shares of Protalix Biotherapeutics Inc (NYSEMKT:PLX) with …